Last updated: September 6, 2026
Antihemophilic factor (recombinant), Fc fusion protein is the factor VIII replacement product sold primarily as ELOCTATE in the United States and ELOCTA in many international markets. The active ingredient is efmoroctocog alfa, also called efmoroctocog alfa or rFVIIIFc. Bioverativ developed the product, Sanofi acquired Bioverativ in 2018, and Swedish Orphan Biovitrum AB, or Sobi, expanded its commercial rights through a later transaction with Sanofi.
The product established a premium position in hemophilia A by extending factor VIII half-life through fusion with the Fc portion of human immunoglobulin G1. Its commercial trajectory has been driven by prophylaxis adoption, reduced infusion frequency, specialist prescribing, and durable reimbursement. Growth has slowed as the market has gained competing extended-half-life factor VIII products, emicizumab prophylaxis, gene therapy, and newer nonfactor therapies.
What is antihemophilic factor recombinant Fc fusion protein?
Antihemophilic factor recombinant Fc fusion protein is an engineered recombinant factor VIII replacement for patients with hemophilia A. The Fc domain extends circulation time by engaging the neonatal Fc receptor recycling pathway.
| Attribute |
ELOCTATE/ELOCTA |
| Active ingredient |
Efmoroctocog alfa |
| Drug class |
Recombinant coagulation factor VIII |
| Technology |
Factor VIII-Fc fusion protein |
| Primary indication |
Control and prevention of bleeding in hemophilia A |
| Administration |
Intravenous infusion |
| Main use |
Routine prophylaxis, on-demand treatment, perioperative management |
| U.S. approval |
June 2014 |
| Original developer |
Biogen, through the Bioverativ business |
| U.S. commercial rights |
Sanofi initially; Sobi acquired U.S. rights in 2024 |
| Regulatory pathway |
Biologics license under the Public Health Service Act |
| U.S. reference product |
ELOCTATE |
The product is not a small-molecule generic product. Follow-on competition must generally use the biosimilar pathway or obtain a separate biologics license. FDA approval of a biosimilar does not automatically eliminate manufacturing, interchangeability, supply-chain, or physician-adoption barriers.
When did ELOCTATE lose exclusivity?
ELOCTATE received FDA approval on June 6, 2014. The reference biologic exclusivity period under the Biologics Price Competition and Innovation Act generally extends for 12 years from first licensure, placing the statutory exclusivity endpoint in June 2026.[1]
That date does not establish a single automatic generic-entry date. Market entry depends on:
- FDA approval of a biosimilar or competing biologic;
- patent scope and validity;
- patent litigation and settlement terms;
- regulatory interchangeability;
- manufacturing capacity;
- payer contracting;
- physician and patient switching behavior.
ELOCTATE’s commercial protection therefore has several layers:
| Protection layer |
Relevance to ELOCTATE |
| FDA biologic exclusivity |
June 2014 approval created a 12-year reference-product exclusivity period |
| Patent protection |
Covers selected molecules, Fc-fusion technology, formulations, uses, and manufacturing processes |
| Clinical adoption |
Established prophylaxis base supports switching costs |
| Treatment continuity |
Hemophilia centers generally prioritize reliable supply and patient-specific dosing |
| Manufacturing |
Recombinant factor VIII production requires specialized cell culture and purification capability |
| Contracting |
National and regional payer contracts influence biosimilar uptake |
ELOCTATE is not listed in the FDA Orange Book because the Orange Book primarily covers approved small-molecule drugs and certain drug-device products. Biologic reference products and biosimilars are tracked in the FDA Purple Book.[2]
What patents protect ELOCTATE and recombinant factor VIII-Fc products?
The patent estate for ELOCTATE is based on multiple patent families rather than a single product patent. Relevant categories include:
Molecule and Fc-fusion patents
These patents can cover the structure of a factor VIII polypeptide linked to an immunoglobulin Fc region. Claims may address the specific fusion architecture, linker, sequence identity, or functional activity.
Formulation patents
Formulation protection can cover stabilizers, buffers, surfactants, lyophilized compositions, reconstitution characteristics, and storage conditions. These patents can complicate biosimilar entry when the competing product seeks to replicate the same presentation or handling profile.
Method-of-use patents
Method claims can address:
- Routine prophylaxis;
- Treatment of acute bleeding;
- Perioperative factor VIII replacement;
- Dosing intervals;
- Pediatric or previously untreated patient populations;
- Prevention of bleeding episodes.
Method-of-use patents are commercially relevant when a biosimilar or competing factor product seeks a label covering the same prophylaxis population.
Manufacturing patents
Manufacturing protection can cover recombinant expression systems, host cells, purification steps, viral inactivation, chromatography, and product-quality controls. These claims are often more difficult to assess from the commercial label but can create practical barriers to biosimilar development.
Geographic coverage
The relevant rights differ by jurisdiction. The United States has the most commercially important biologic litigation framework, while Europe relies on national patent enforcement despite centralized marketing authorization through the European Medicines Agency. Japan, Canada, Australia, and major European markets each require separate patent and regulatory analysis.
A definitive live patent-expiration table requires a current family-level review of USPTO, WIPO, European Patent Office, national registers, and litigation dockets. Public product materials alone do not establish the complete enforceable estate.
How strong is the ELOCTATE patent estate?
ELOCTATE has a moderately strong commercial protection profile, but its long-term position depends less on basic factor VIII composition claims than on layered rights and market execution.
Strengths
- First approval in 2014 created a substantial early-mover advantage.
- The Fc-fusion architecture is clinically differentiated from standard half-life factor VIII.
- Intravenous prophylaxis remains an established treatment pathway.
- Manufacturing is technically complex and requires validated biologic processes.
- The patient population is concentrated in specialized hemophilia treatment centers.
- Treatment continuity and individual pharmacokinetic response reduce immediate switching.
Weaknesses
- Fc-fusion technology is not exclusive to one company.
- Other extended-half-life factor VIII products compete for the same patients.
- Emicizumab provides subcutaneous nonfactor prophylaxis for hemophilia A patients with and without inhibitors.
- Gene therapy introduces a potential one-time-treatment alternative for eligible adults.
- Biosimilar competition can reduce price even without full interchangeability.
- The product has no protection from the broader decline in factor VIII demand caused by nonfactor therapies.
The estate is stronger against rapid, broad substitution than against gradual pricing erosion. A biosimilar may not need to capture a majority of the installed base to pressure net pricing, hospital contracts, and payer formularies.
How has the financial trajectory developed?
ELOCTATE was one of Bioverativ’s two principal commercial products, together with ALPROLIX, a recombinant factor IX Fc fusion protein. Bioverativ reported ELOCTATE net product revenue of approximately $583 million in 2017, compared with approximately $447 million in 2016.[3] The increase reflected continued prophylaxis adoption and the commercial expansion of the extended-half-life factor VIII category.
Sanofi acquired Bioverativ in 2018 for approximately $11.6 billion, valuing the company on the strength of its hemophilia portfolio and its specialized commercial infrastructure.[4] After the acquisition, ELOCTATE became part of Sanofi’s specialty-care portfolio. Sanofi’s reporting structure and currency conversion changed over time, making direct year-to-year comparisons less transparent than the former Bioverativ disclosures.
Financial trajectory
| Period |
Corporate event or financial driver |
Commercial implication |
| 2014 |
FDA approval |
ELOCTATE entered the U.S. extended-half-life factor VIII market |
| 2016 |
Pre-transaction growth phase |
Revenue benefited from conversion of patients from standard half-life factor VIII |
| 2017 |
Bioverativ reported about $583 million in ELOCTATE revenue |
Product became a major standalone hemophilia asset |
| 2018 |
Sanofi acquired Bioverativ for about $11.6 billion |
Ownership shifted to a global specialty-pharmaceutical company |
| 2019-2022 |
Mature-brand period |
Growth depended on international penetration, prophylaxis persistence, and pricing |
| 2023-2024 |
Sanofi-Sobi rights restructuring |
Commercial economics became divided by geography |
| 2026 |
U.S. biologic exclusivity endpoint |
Biosimilar and competing-biologic risk increases, subject to patents and FDA review |
The product’s financial profile has shifted from high-growth launch asset to mature specialty biologic. Revenue is likely to remain durable where patients value reduced infusion frequency, but percentage growth should be lower than during the initial conversion period.
What market dynamics affect ELOCTATE sales?
Extended-half-life conversion
ELOCTATE initially benefited from conversion away from standard half-life recombinant factor VIII products. Fewer scheduled infusions can improve treatment convenience and support prophylaxis adherence. The economic benefit is partly offset by high unit pricing and patient-specific dosing requirements.
Nonfactor prophylaxis
Emicizumab is the most important nonfactor competitor in hemophilia A. It is administered subcutaneously and can reduce the need for routine intravenous factor infusions. It does not eliminate the need for factor VIII in every clinical situation, especially surgery, acute bleeding, and certain patients requiring replacement therapy.
The competitive effect is therefore segmented:
- Routine prophylaxis is exposed to emicizumab substitution.
- Acute and perioperative factor demand remains more resilient.
- Patients with established factor VIII response may remain on ELOCTATE.
- Patients prioritizing fewer intravenous infusions are more likely to switch.
Gene therapy
Hemophilia A gene therapies create a high-impact but narrower competitive threat. Eligibility, durability, liver-health requirements, administration-center capacity, reimbursement, and long-term factor expression affect uptake. Gene therapy is more likely to reduce future factor utilization in selected adults than to eliminate the entire factor VIII market in the near term.
Payer pressure
Factor VIII products have high annual treatment costs. Payers can use preferred-product contracts, specialty-pharmacy distribution, step edits, and rebate negotiations to influence product selection. A biosimilar or lower-priced extended-half-life competitor would increase negotiating pressure even before broad clinical substitution occurs.
Patient segmentation
ELOCTATE’s financial performance depends on patient mix:
| Segment |
Exposure to ELOCTATE |
| Adult prophylaxis patients |
High value, but exposed to emicizumab and gene therapy |
| Pediatric patients |
Long treatment duration supports lifetime value, but switching decisions are clinically conservative |
| Patients with inhibitors |
Lower direct relevance because nonfactor therapy may dominate |
| Surgical patients |
Factor replacement remains important |
| On-demand patients |
Lower revenue intensity than routine prophylaxis |
| Previously untreated patients |
Important for long-term share but vulnerable to initial product selection |
Which companies compete with ELOCTATE?
ELOCTATE competes across three product groups.
Extended-half-life factor VIII
- Takeda’s ADVATE and ADYNOVATE;
- Bayer’s KOVALTRY and JIVI;
- CSL Behring’s AFSTYLA;
- Novo Nordisk’s ESPEROCT;
- Other regional recombinant factor VIII products.
These products compete on half-life, dosing interval, inhibitor development, supply reliability, pharmacokinetics, and contracting.
Standard half-life factor VIII
Standard half-life products remain relevant because of physician familiarity, patient response, formulary position, and lower acquisition cost in some markets. Their presence limits the ability of any one extended-half-life product to expand indefinitely.
Nonfactor and gene therapies
- Roche’s HEMLIBRA, or emicizumab;
- Gene therapies for eligible hemophilia A patients;
- Investigational rebalancing agents and other nonfactor products.
These alternatives challenge the volume assumptions behind factor VIII sales rather than only competing on price.
What is the FDA regulatory status of ELOCTATE?
FDA approved ELOCTATE in 2014 for control and prevention of bleeding episodes, perioperative management, and routine prophylaxis in adults and children with hemophilia A.[5] It is a licensed biologic, not a conventional chemical drug.
The principal regulatory issues are:
- Reference-product exclusivity under the BPCI Act;
- Potential biosimilar applications;
- Interchangeability determinations;
- Immunogenicity and inhibitor monitoring;
- Manufacturing consistency;
- Viral safety and product-quality controls;
- Labeling for pediatric and perioperative use.
No automatic substitution should be assumed from biosimilar approval alone. Pharmacy substitution generally depends on an FDA interchangeability designation and state law.
What patent litigation and settlement risks affect ELOCTATE?
The principal litigation risk is likely to arise from a future biosimilar or competing biologic application. The BPCIA patent-exchange process can identify disputes involving composition, formulation, manufacturing, and use patents. Litigation timing can delay commercial entry beyond the 2026 statutory exclusivity endpoint.
Potential settlement structures include:
- Delayed entry before full patent expiry;
- Geographic launch rights;
- Royalty-bearing licenses;
- Limited indications;
- Non-exclusive manufacturing arrangements;
- Staged entry tied to patent outcomes.
A settlement can preserve revenue for the reference-product holder while giving a challenger a defined launch date. It can also reduce litigation costs and provide greater market certainty.
What licensing deals affect the product’s commercial value?
Bioverativ’s original development and commercialization history connected the product to Biogen’s biologics capabilities. Sanofi’s acquisition of Bioverativ transferred ownership of ELOCTATE and ALPROLIX to Sanofi.
Sobi later expanded its rights in the hemophilia portfolio. In 2024, Sobi announced an agreement to acquire Sanofi’s U.S. rights to ELOCTATE and ALPROLIX for approximately $900 million, subject to transaction terms and closing conditions.[6] The transaction increased Sobi’s control over the U.S. commercial economics while Sanofi retained rights in other markets under the parties’ broader arrangement.
This structure matters financially because reported revenue, royalties, transfer pricing, and regional profitability may differ by geography and corporate owner. U.S. rights are particularly valuable because the market has high treatment intensity and concentrated specialist prescribing.
What generic or biosimilar launch scenarios exist?
Early competitive entry after statutory exclusivity
A biosimilar could seek approval after June 2026, subject to patent litigation and FDA review. The initial effect would more likely be contracting pressure and selective switching than immediate erosion of all ELOCTATE sales.
Delayed entry after patent settlement
A settlement could defer entry for several years. ELOCTATE would retain branded revenue during the delay but face launch preparation, legal costs, and payer negotiations.
Non-interchangeable biosimilar launch
A biosimilar without interchangeability could enter through physician-directed prescribing. Uptake would depend on evidence, price discount, treatment-center protocols, and payer incentives.
Interchangeable biosimilar launch
An interchangeable product would create greater substitution risk, particularly in stable prophylaxis patients and payer-controlled channels. The reference product could respond through rebates, patient services, supply commitments, and contracting.
Nonfactor displacement
Emicizumab and future agents could reduce ELOCTATE utilization without a direct biosimilar launch. This is the main volume risk for routine prophylaxis.
How does ELOCTATE compare with emicizumab and gene therapy?
| Factor |
ELOCTATE |
Emicizumab |
Gene therapy |
| Treatment type |
Factor VIII replacement |
Bispecific nonfactor antibody |
One-time genetic treatment |
| Administration |
Intravenous |
Subcutaneous |
Specialist-center infusion |
| Routine dosing |
Repeated prophylaxis |
Scheduled subcutaneous dosing |
Single administration |
| Acute bleeding utility |
Established |
Requires specific management protocols |
Variable after treatment |
| Manufacturing barrier |
High recombinant biologic complexity |
High biologic complexity |
Very high viral-vector complexity |
| Revenue profile |
Recurring product revenue |
Recurring product revenue |
Potentially front-loaded revenue |
| Main limitation |
Infusion burden and cost |
Does not replace factor in all settings |
Eligibility, durability, reimbursement |
| Competitive threat |
High in prophylaxis |
High for factor utilization |
Selective but financially material |
What is the revenue exposure and investment outlook?
ELOCTATE remains a valuable specialty biologic, but its growth profile is mature. The commercial outlook has four opposing forces:
- Durable prophylaxis demand and treatment-center loyalty support recurring revenue.
- Emicizumab reduces intravenous factor use in routine prophylaxis.
- Gene therapy can remove selected high-value patients from chronic factor treatment.
- Biosimilar and competing-factor entry can pressure price and market share after the exclusivity period.
The most likely financial trajectory is stable-to-declining revenue over the medium term, with the slope determined by biosimilar timing, payer discounts, nonfactor adoption, and Sobi’s ability to defend U.S. share. A sharp collapse is less likely than progressive erosion because ELOCTATE retains clinical utility in surgery, breakthrough bleeding, pediatric care, and patients who prefer or require factor VIII replacement.
Key Takeaways
- ELOCTATE is the principal commercial product based on efmoroctocog alfa, a recombinant factor VIII-Fc fusion protein.
- FDA approval occurred in June 2014, placing the BPCI Act reference-biologic exclusivity endpoint in June 2026.
- ELOCTATE generated approximately $583 million in Bioverativ-reported revenue in 2017.
- Sanofi acquired Bioverativ for approximately $11.6 billion in 2018.
- Sobi acquired Sanofi’s U.S. ELOCTATE and ALPROLIX rights for approximately $900 million in 2024.
- The product is regulated through the Purple Book framework, not the Orange Book.
- Emicizumab is the largest direct threat to routine prophylaxis demand.
- Gene therapy creates selective long-term volume risk.
- Patent protection is layered across molecule, formulation, use, and manufacturing claims.
- The principal post-2026 risk is gradual price and share erosion rather than immediate market disappearance.
FAQs
Is ELOCTATE a biosimilar?
No. ELOCTATE is an original licensed biologic and functions as the reference product for any future biosimilar development against the same biologic reference.
Does ELOCTATE have an Orange Book listing?
No. ELOCTATE is regulated as a biologic and is tracked through the FDA Purple Book rather than the Orange Book.
Can emicizumab replace ELOCTATE in surgery?
Not in every case. Factor VIII replacement remains clinically important for many surgical procedures and acute bleeding situations, subject to hematologist-directed protocols.
Who owns ELOCTATE in the United States?
Sobi acquired Sanofi’s U.S. rights to ELOCTATE and ALPROLIX in a transaction announced in 2024. Ownership and commercialization outside the United States follow separate regional arrangements.
What is the largest long-term risk to ELOCTATE revenue?
The largest structural risk is combined displacement from nonfactor prophylaxis, gene therapy in eligible patients, and biosimilar or competing-factor price competition after the reference-product exclusivity period.
References
- U.S. Food and Drug Administration. (2024). Reference product exclusivity for biological products. https://www.fda.gov
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
- Bioverativ Inc. (2018). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for fiscal year 2017. U.S. Securities and Exchange Commission.
- Sanofi. (2018). Sanofi completes acquisition of Bioverativ. https://www.sanofi.com
- U.S. Food and Drug Administration. (2014). ELOCTATE prescribing information. https://www.accessdata.fda.gov
- Swedish Orphan Biovitrum AB. (2024). Sobi to acquire U.S. rights to Eloctate and Alprolix from Sanofi. https://www.sobi.com
